Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZDHHC20 | Q5W0Z9 | 2/20 | 0.41 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4316811 | 0.92 | ZDHHC20 (0.41) | ZDHHC20ZDHHC2 | |
| SCHEMBL907451 | 0.86 | ZDHHC20 (0.40) | ZDHHC20ZDHHC2CA12CA1CA9 | |
| SCHEMBL9763751 | 0.86 | ZDHHC20 (0.37) | ZDHHC20ZDHHC2LMNA | |
| SCHEMBL23303408 | 0.83 | ZDHHC20 (0.35) | ZDHHC20ZDHHC2 | |
| SCHEMBL16776772 | 0.80 | ZDHHC20 (0.56) | ZDHHC20ZDHHC2CA12CA1CA9 | |
| SCHEMBL633117 | 0.80 | ZDHHC20 (0.51) | ZDHHC20ZDHHC2CA12CA1CA9 | |
| SCHEMBL907561 | 0.80 | ZDHHC20 (0.30) | ZDHHC20ZDHHC2 | |
| SCHEMBL3844670 | 0.80 | CA12 (0.36) | CA12CA1CA9CYP1A2CYP3A4 | |
| SCHEMBL15655347 | 0.79 | ZDHHC20 (0.42) | ZDHHC20ZDHHC2 | |
| SCHEMBL16776745 | 0.79 | ZDHHC20 (0.59) | ZDHHC20ZDHHC2CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3556731-A1 | METHOD FOR THE CHEMICAL MODIFICATION OF METAL OXIDE SURFACES | Justus-Liebig-Universität Gießen (DE) | 2019-10-23 | — | — | EP | disclosed |
| US-8367748-B2 | Surface-modified fillers | IVOCLAR VIVADENT AG (LI) | 2013-02-05 | — | — | US | disclosed |
| US-8367748-B2 | Surface-modified fillers | IVOCLAR VIVADENT AG (LI) | 2013-02-05 | — | — | US | disclosed |
| EP-2080503-B1 | Dental materials with surface functional fillers | IVOCLAR VIVADENT AG (LI) | 2011-09-14 | — | — | EP | disclosed |
| EP-2277496-A1 | Dental material containing surface-modified fillers | Ivoclar Vivadent AG (LI) | 2011-01-26 | — | — | EP | disclosed |
| EP-1716836-B1 | Surface-modified fillers | IVOCLAR VIVADENT AG (LI) | 2011-01-19 | — | — | EP | disclosed |
| US-20090186960-A1 | DENTAL MATERIALS WITH SURFACE-FUNCTIONALIZED FILLERS | IVOCLAR VIVADENT AG (LI) | 2009-07-23 | — | — | US | disclosed |
| EP-2080503-A1 | Dental materials with surface functional fillers | Ivoclar Vivadent AG (LI) | 2009-07-22 | — | — | EP | disclosed |
| EP-1716836-A1 | Surface-modified fillers | Ivoclar Vivadent AG (LI) | 2006-11-02 | — | — | EP | disclosed |
| US-20060247329-A1 | Surface-modified fillers | IVOCLAR VIVADENT AG (LI) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186960-A1 | DENTAL MATERIALS WITH SURFACE-FUNCTIONALIZED FILLERS | ITGAM, ITGA5, ITGA1 | ZDHHC20 3076/4885ZDHHC2 3054/4885CA12 118/4885 |
| US-20060247329-A1 | Surface-modified fillers | MSR1, HRH4, OR10J3 | ZDHHC20 1730/4885ZDHHC2 3218/4885CA12 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.